Otsuka (OTCMKTS:OTSKY) Cut to “Strong Sell” at Zacks Research

Zacks Research downgraded shares of Otsuka (OTCMKTS:OTSKY) from a hold rating to a strong sell rating in a research note released on Monday morning,Zacks.com reports.

OTSKY has been the subject of several other research reports. UBS Group upgraded shares of Otsuka to a “hold” rating in a research report on Tuesday, January 27th. Morgan Stanley raised shares of Otsuka to an “overweight” rating in a research note on Friday, January 23rd. Finally, The Goldman Sachs Group cut shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, February 27th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Reduce”.

Otsuka Stock Performance

Shares of OTSKY opened at $32.80 on Monday. Otsuka has a 12 month low of $21.64 and a 12 month high of $34.93. The stock has a fifty day moving average price of $30.63 and a 200 day moving average price of $28.74.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.